Opinion on Therapy Area in South and Central America

Published within

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

ICAAC 2010: dominance of cross-class combinations intensifies challenges for standalone drugs in HIV

HIV therapy has come a long way since the introduction of combination therapy in the mid-1990s, with more than 20 HIV drugs now on the market. In September 2010, at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Datamonitor identified a number of significant developments in the field of HIV treatment.

Published By Datamonitor
02 Nov 2010
ResearchWire
ResearchWire

Hypertension: innovation left to Novartis

Published By Datamonitor
16 Jun 2006
ResearchWire
ResearchWire

HRT market: innovative treatment options to restore growth

Published By Datamonitor
25 Apr 2008
ResearchWire
ResearchWire

Hospital antibiotics: overall decline, but strong growth in some areas

Published By Datamonitor
06 Sep 2007
ResearchWire
ResearchWire

Hospital acquired infections: crucial need for gram-negative antibacterials

Published By Datamonitor
11 Apr 2007
Expert View
Expert View

Hope for an Alzheimer's breakthrough remains despite Dimebon's failure

A Phase III trial evaluating Medivation/Pfizer's Dimebon in Alzheimer's disease has failed to meet any of its clinical endpoints, despite high hopes of the drug after promising Phase II results. This is a significant setback for Dimebon's developers, particularly Medivation, but hope for the millions of Alzheimer's sufferers and their caregivers remains in the pipeline.

Published By Datamonitor
04 Mar 2010
CommentWire
CommentWire

HIV: US senate may face more pressure

Many patient advocacy groups argue that the US is not contributing sufficiently to HIV prevention and treatment, despite the recent budget approval. Furthermore, most of the major HIV drug manufacturers are either US based or heavily involved in the US - a factor likely to provide additional pressure for increased funding.

Published By Datamonitor
21 May 2003
CommentWire
CommentWire

HIV patents: no solution - yet

While the WTO has not yet made a breakthrough on the issue of patent-free HIV drugs for developing economies, something must be done to alleviate the human and economic cost of the HIV epidemic. Western pharma companies will inevitably lose out - the only question is how well their profit maintenance strategies can cushion the blow.

Published By Datamonitor
22 Oct 2002
Expert View
Expert View

HIV market: collaborative combinations

Two new HIV drugs, from Tibotec and Gilead, have been shown to be viable late-stage pipeline candidates. However, both TMC278 and elvitegravir are set to compete head-to-head against more widely-used competitors. In the longer term, both candidates could improve usage and penetration through use in collaborative combination therapies.

Published By Datamonitor
12 Mar 2007
CommentWire
CommentWire

HIV drugs: patent disputes escalate

Published By Datamonitor
28 Aug 2001

« | ... | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | ... | » »|

No help is available.